Advertisement
GSK or PFE or TEVA
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 2 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s), and TEVA’s FA Score reflects 1 green FA rating(s).
- GSK’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 1 green, 4 red.
- TEVA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 7 bullish TA indicator(s), and TEVA’s TA Score reflects 6 bullish TA indicator(s).
- GSK’s TA Score: 6 bullish, 4 bearish.
- PFE’s TA Score: 7 bullish, 4 bearish.
- TEVA’s TA Score: 6 bullish, 4 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а +1.46% price change this week, while PFE (@Pharmaceuticals: Major) price change was +0.28% , and TEVA (@Pharmaceuticals: Generic) price fluctuated +0.33% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.60%. For the same industry, the average monthly price growth was +2.15%, and the average quarterly price growth was +12.37%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.56%. For the same industry, the average monthly price growth was +10.78%, and the average quarterly price growth was +74.70%.
Reported Earning Dates
GSK is expected to report earnings on Oct 29, 2025.
PFE is expected to report earnings on Nov 04, 2025.
TEVA is expected to report earnings on Nov 06, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (-0.60% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Pharmaceuticals: Generic (+3.56% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| GSK | PFE | TEVA | |
| Capitalization | 80.6B | 143B | 21.2B |
| EBITDA | 8.61B | 20.2B | 1.9B |
| Gain YTD | 21.185 | -0.141 | -17.786 |
| P/E Ratio | 17.72 | 13.30 | N/A |
| Revenue | 31.6B | 63.8B | 16.6B |
| Total Cash | 3.62B | 13.2B | 2.16B |
| Total Debt | 17.4B | 60.9B | 17.5B |
GSK | PFE | TEVA | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 22 | 18 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 4 Undervalued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 66 | 100 | 59 | |
SMR RATING 1..100 | 39 | 62 | 92 | |
PRICE GROWTH RATING 1..100 | 51 | 52 | 48 | |
P/E GROWTH RATING 1..100 | 25 | 97 | 12 | |
SEASONALITY SCORE 1..100 | 85 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (4) in the Pharmaceuticals Major industry is in the same range as GSK (6) in the Pharmaceuticals Major industry, and is significantly better than the same rating for TEVA (73) in the Pharmaceuticals Generic industry. This means that PFE's stock grew similarly to GSK’s and significantly faster than TEVA’s over the last 12 months.
TEVA's Profit vs Risk Rating (59) in the Pharmaceuticals Generic industry is in the same range as GSK (66) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that TEVA's stock grew similarly to GSK’s and somewhat faster than PFE’s over the last 12 months.
GSK's SMR Rating (39) in the Pharmaceuticals Major industry is in the same range as PFE (62) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for TEVA (92) in the Pharmaceuticals Generic industry. This means that GSK's stock grew similarly to PFE’s and somewhat faster than TEVA’s over the last 12 months.
TEVA's Price Growth Rating (48) in the Pharmaceuticals Generic industry is in the same range as GSK (51) in the Pharmaceuticals Major industry, and is in the same range as PFE (52) in the Pharmaceuticals Major industry. This means that TEVA's stock grew similarly to GSK’s and similarly to PFE’s over the last 12 months.
TEVA's P/E Growth Rating (12) in the Pharmaceuticals Generic industry is in the same range as GSK (25) in the Pharmaceuticals Major industry, and is significantly better than the same rating for PFE (97) in the Pharmaceuticals Major industry. This means that TEVA's stock grew similarly to GSK’s and significantly faster than PFE’s over the last 12 months.
| GSK | PFE | TEVA | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 49% | 2 days ago 47% | 2 days ago 56% |
| Stochastic ODDS (%) | 2 days ago 41% | 2 days ago 53% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 66% | 2 days ago 54% | 2 days ago 68% |
| MACD ODDS (%) | 2 days ago 52% | 2 days ago 52% | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 59% | 2 days ago 58% | 2 days ago 72% |
| TrendMonth ODDS (%) | 2 days ago 53% | 2 days ago 53% | 2 days ago 68% |
| Advances ODDS (%) | 5 days ago 58% | 5 days ago 57% | 6 days ago 71% |
| Declines ODDS (%) | 21 days ago 54% | 27 days ago 60% | 2 days ago 72% |
| BollingerBands ODDS (%) | 2 days ago 55% | 2 days ago 60% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 48% | 2 days ago 58% | 2 days ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| REMX | 61.23 | 2.35 | +3.99% |
| VanEck Rare Earth & Strat Mtls ETF | |||
| PCQ | 8.26 | 0.02 | +0.24% |
| Pimco California Municipal Income Fund | |||
| KCSH | 25.13 | N/A | N/A |
| Kraneshares Sust Ultra Shrt Dur Idx ETF | |||
| SOXL | 27.30 | -0.15 | -0.55% |
| Direxion Daily Semicondct Bull 3X ETF | |||
| CCSO | 23.85 | -0.17 | -0.72% |
| Carbon Collective Climate Sol US Eq ETF | |||